This session features industry-sponsored preclinical and translational research spanning novel therapeutics for Alagille syndrome, PSC, alcohol use disorder, and decompensated cirrhosis, plus hepatocyte engineering advances.

Harrys A. Torres, MD, FACP, FIDSA, FAASLD is a Professor of Medicine in the Department of Infectious Diseases, Infection Control, and Employee Health and an Adjunct Professor in the Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and infectious disease, with additional accreditations in HIV/AIDS and Tropical Medicine and Hygiene.

I completed medical school at Tufts University school of Medicine, Internal Medicine residency at University of Pennsylvania, and Gastroenterology and Transplant Hepatology fellowships at Yale University. I am an attending transplant hepatologist at the University of Washington where I serve as the medical director for Northwest Hepatology and as core faculty for the GI fellowship. I am also a part of a multidisciplinary group for hereditary hemorrhagic telangiectasia working to build a center of excellence.

William Bernal is Professor of Liver Critical Care Medicine in the Liver Intensive Therapy Unit at the Institute of Liver Studies at Kings College Hospital in London UK. He is part of a small consultant team running a 19 bedded specialist intensive care unit devoted to the care of critically-ill patients with severe liver and pancreatic disease, which serves one of the largest liver transplantation programs in Europe

Robin is a Family Nurse Practitioner with over 24 years of clinical experience. She received her MSN from The Johns Hopkins School of Nursing where she was a National Health Service Corps Scholar and a Peace Corps Fellow. Robin celebrated 10 years as a hepatology NP at UC San Diego Health in August of this year.

Andreas Zori is a transplant hepatologist at the University of Florida where he serves as the associate program director for both the Gastroenterology and Transplant hepatology fellowships. His research and clinical focus is primarily on alcohol associated liver diseases in the setting of liver transplantation but also include Hereditary Hemorrhagic Telangiectasia and transplant oncology.

Liver scientist dedicated to elucidating the fundamental mechanisms underlying the initiation and progression of chronic liver disease. My research focuses on the hepatic secretome, damage-associated molecular patterns (DAMPs), immune cell activation, immune suppression, and immune tolerance across the continuum of liver injury, from early-stage disease to advanced cirrhosis. I am particularly interested in understanding how dysregulated immune responses and intercellular signaling networks influence disease progression and clinical outcomes.

Professor Silvia Sookoian, MD, PhD, is a Senior Research Scientist at CONICET (National Scientific and Technical Research Council) and a graduate of the University of Buenos Aires School of Medicine (MD, Magna Cum Laude). As a dedicated physician-scientist, her professional role focuses on the translation of scientific knowledge in hepatology directly into patient care. Her current clinical and translational research centers on the genetic, epigenetic, and molecular mechanisms driving the pathogenesis and progression of MASLD. Dr.

Professor Adams (MBBS, FRACP, PhD) is a Consultant Hepatologist at Sir Charles Gairdner Hospital and lead of the Liver Research Group in the Medical School, University of Western Australia (UWA). His research interests focus on clinical and translational aspects of MASLD and non-invasive assessment of liver disease where he has >250 research publications.